CJS07
2021-09-10
Prizer,s share prize is too low despite its good performance
UK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis<blockquote>英国MHRA授予辉瑞Cibinqo上市许可，用于患有中度至重度特应性皮炎的成人和青少年</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
人之道旅行者
2021-09-11
人之道旅行者
能赚就是福，积少成多，聚沙成塔嘛，慢慢来
王无所不知
2021-09-11
王无所不知
这是正常现象啦，不是还存在高估低估的情况嘛
李苗苗
2021-09-10
李苗苗
有一些股票，可能高高不到哪儿去，低低不到哪儿去，就当赚个茶水钱吧
九洲仙人
2021-09-10
九洲仙人
这也算是正常情况吧，我就没见过哪些特别高的，高到哪去
波king
2021-09-10
波king
确实如此，让人感到有些失望
什么也没有了～
APP内打开
发表看法
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":883890839,"tweetId":"883890839","gmtCreate":1631231240721,"gmtModify":1632883837595,"author":{"id":3575236051539340,"idStr":"3575236051539340","authorId":3575236051539340,"authorIdStr":"3575236051539340","name":"CJS07","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Prizer,s share prize is too low despite its good performance </p></body></html>","htmlText":"<html><head></head><body><p>Prizer,s share prize is too low despite its good performance </p></body></html>","text":"Prizer,s share prize is too low despite its good performance","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":5,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/883890839","repostId":2166310922,"repostType":2,"repost":{"id":"2166310922","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1631185740,"share":"https://www.laohu8.com/m/news/2166310922?lang=zh_CN&edition=full","pubTime":"2021-09-09 19:09","market":"hk","language":"en","title":"UK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis<blockquote>英国MHRA授予辉瑞Cibinqo上市许可，用于患有中度至重度特应性皮炎的成人和青少年</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2166310922","media":"T-Reuters","summary":"Pfizer Inc :Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults ","content":"<p><html><body>Pfizer Inc <pfe.n>:Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults And Adolescents With Moderate To Severe Atopic Dermatitis.Pfizer Inc - Abrocitinib Is Licensed In Great Britain In Recommended Doses Of 100Mg And 200Mg..</pfe.n></p><p><blockquote><html><body>辉瑞公司<pfe.n>：英国Mhra授予辉瑞Cibinqo上市许可®（Abrocitinib）适用于患有中度至重度特应性皮炎的成人和青少年。辉瑞公司-Abrocitinib在英国获得许可，推荐剂量为100毫克和200毫克..</pfe.n></body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis<blockquote>英国MHRA授予辉瑞Cibinqo上市许可，用于患有中度至重度特应性皮炎的成人和青少年</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis<blockquote>英国MHRA授予辉瑞Cibinqo上市许可，用于患有中度至重度特应性皮炎的成人和青少年</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time smaller\">2021-09-09 19:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>Pfizer Inc <pfe.n>:Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults And Adolescents With Moderate To Severe Atopic Dermatitis.Pfizer Inc - Abrocitinib Is Licensed In Great Britain In Recommended Doses Of 100Mg And 200Mg..</pfe.n></p><p><blockquote><html><body>辉瑞公司<pfe.n>：英国Mhra授予辉瑞Cibinqo上市许可®（Abrocitinib）适用于患有中度至重度特应性皮炎的成人和青少年。辉瑞公司-Abrocitinib在英国获得许可，推荐剂量为100毫克和200毫克..</pfe.n></body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","PFE":"辉瑞","CGEM":"Cullinan Therapeutics","LHDX":"Lucira Health, Inc."},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166310922","content_text":"Pfizer Inc :Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults And Adolescents With Moderate To Severe Atopic Dermatitis.Pfizer Inc - Abrocitinib Is Licensed In Great Britain In Recommended Doses Of 100Mg And 200Mg..","news_type":1,"symbols_score_info":{"SANA":0.9,"CGEM":0.9,"APR":0.9,"LABP":0.9,"LHDX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":159,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":51,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":5830472,"commentId":"5830472","gmtCreate":1631347059110,"gmtModify":1631347059110,"authorId":9000000000000212,"author":{"id":9000000000000212,"idStr":"9000000000000212","authorId":9000000000000212,"name":"人之道旅行者","avatar":"https://static.tigerbbs.com/121023702578466a4f9263fdea5e0fd4","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883890839,"objectIdStr":"883890839","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"能赚就是福，积少成多，聚沙成塔嘛，慢慢来","text":"能赚就是福，积少成多，聚沙成塔嘛，慢慢来","html":"能赚就是福，积少成多，聚沙成塔嘛，慢慢来","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":5830469,"commentId":"5830469","gmtCreate":1631347037722,"gmtModify":1631347037722,"authorId":9000000000000161,"author":{"id":9000000000000161,"idStr":"9000000000000161","authorId":9000000000000161,"name":"王无所不知","avatar":"https://static.tigerbbs.com/4ec8b377ac9ad32d941432c2e87c3f1b","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883890839,"objectIdStr":"883890839","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"这是正常现象啦，不是还存在高估低估的情况嘛","text":"这是正常现象啦，不是还存在高估低估的情况嘛","html":"这是正常现象啦，不是还存在高估低估的情况嘛","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":5817356,"commentId":"5817356","gmtCreate":1631261281853,"gmtModify":1631261281853,"authorId":3479274710327383,"author":{"id":3479274710327383,"idStr":"3479274710327383","authorId":3479274710327383,"name":"李苗苗","avatar":"https://static.laohu8.com/picture41","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883890839,"objectIdStr":"883890839","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"有一些股票，可能高高不到哪儿去，低低不到哪儿去，就当赚个茶水钱吧","text":"有一些股票，可能高高不到哪儿去，低低不到哪儿去，就当赚个茶水钱吧","html":"有一些股票，可能高高不到哪儿去，低低不到哪儿去，就当赚个茶水钱吧","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":5811843,"commentId":"5811843","gmtCreate":1631232742804,"gmtModify":1631232742804,"authorId":9000000000000148,"author":{"id":9000000000000148,"idStr":"9000000000000148","authorId":9000000000000148,"name":"九洲仙人","avatar":"https://static.tigerbbs.com/70eb8e5a109296fe82a90563211f430b","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883890839,"objectIdStr":"883890839","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"这也算是正常情况吧，我就没见过哪些特别高的，高到哪去","text":"这也算是正常情况吧，我就没见过哪些特别高的，高到哪去","html":"这也算是正常情况吧，我就没见过哪些特别高的，高到哪去","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":5811814,"commentId":"5811814","gmtCreate":1631232638729,"gmtModify":1631232638729,"authorId":3479274789332061,"author":{"id":3479274789332061,"idStr":"3479274789332061","authorId":3479274789332061,"name":"波king","avatar":"https://static.tigerbbs.com/5085eb698e32f93414f5f47622156f8d","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883890839,"objectIdStr":"883890839","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"确实如此，让人感到有些失望","text":"确实如此，让人感到有些失望","html":"确实如此，让人感到有些失望","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/883890839"}
精彩评论